A commissioning protocol for portal imaging-based radiotherapy in vivo dosimetry systems

基于门户成像的放射治疗体内剂量测定系统的调试规程

阅读:2

Abstract

BACKGROUND AND PURPOSE: With the availability of commercial electronic portal imaging detector-based in vivo dosimetry (EPID-based IVD) solutions, many radiotherapy departments are adopting this technology. However, comprehensive commissioning guidance is lacking. This study aims to provide a protocol for testing the accuracy and sensitivity of EPID-based IVD systems. MATERIAL AND METHODS: The protocol was tested across four institutions using two different systems. Accuracy was evaluated with homogeneous slab phantoms using different square regular fields, and clinical plans in a CIRS lung phantom. Multiple forward and back-projected algorithm implementations were assessed for different energies. Sensitivity analysis in the lung phantom examined responses to setup errors, anatomical variations, and delivery errors. RESULTS: In homogeneous phantoms, over 85 % of pixels passed the 5 %/2mm gamma criteria, except for the 2x2 cm(2) field. In the lung phantom, all systems and implementations achieved over 95 %-pixel pass rates at the 2 %/2mm criterion for volumetric modulated arc therapy (VMAT) plans. For conformal radiation therapy (3DCRT) plans, one system implementation showed poor accuracy, with over 90 % agreement only at the 5 %/2mm criterion. Considering all systems and implementations, average sensitivity and specificity for CRT plans ranged from 0.92 and 0.42 (at 2 %/2mm) to 0.71 and 0.52 (at 5 %/2mm), while for VMAT plans ranged from 0.41 and 0.81 (at 2 %2mm) to 0.37 and 0.81 (at 5 %/2mm). CONCLUSION: We successfully developed a protocol to commission EPID IDV systems. It was found that not all systems and implementations achieved satisfactory accuracy and sensitivity, emphasising the need for thorough commissioning and benchmarking.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。